Table 1 Summary of the classifications used for the different phases

Phase 1A (Assess decline in prevalence)

Faster decline

Prevalence declining significantly faster than predicted

On track

Prevalence not significantly different from predicted

Delayed decline

Prevalence declining significantly slower than predicted

Phase 1B (Determine if treatment can be stopped)

Stopping criteria met

Area prevalence significantly below 1.4 % and maximum stratum prevalence significantly below 5 %

Close to elimination

Above thresholds not met but <1.4 % mf positives in sample

Stopping criteria not met

Above thresholds not met and >1.4 % mf positives in sample

Overall classification using all data (Assess progress towards elimination)

Stopping criteria met

Stopping criteria met in phase 1B

Close to elimination

Close to elimination in phase 1B or <1.4 % mf positives in phase 1A

On track but some time to go

Prevalence decline faster/on track and > 1.4 % mf positives in sample

Unsatisfactory

Prevalence decline delayed and > 1.4 % mf positives in sample